Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of necitumumab plus gemcitabine-cisplatin in first-line stage IV squamous NSCLC
NL-OMON40000Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of necitumumab, gemcitabine and cisplatin in Pulmonary squamous cell carcinoma, sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate. Started Jun 2013; status: active, not recruiting.
02
Drugs
necitumumabgemcitabinecisplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON40000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40000.